Loading
A phase 3 trial of Orelabrutinib, Rituximab and Lenalidomide in non-Hodgkin lymphoma, run by Beijing InnoCare Pharma Tech Co., Ltd., now recruiting.
Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma is a phase 3 interventional study registered as NCT06082102 by Beijing InnoCare Pharma Tech Co., Ltd., with 324 participants planned, started 2023-12-19 and due to reach its primary completion in 2028-08-31. Interventions recorded: Orelabrutinib, Rituximab and Lenalidomide.
Shares Orelabrutinib, InnoCare Pharma, Small-molecule kinase inhibitors and the tag pipeline.
Shares PROTACs & molecular glues (targeted protein degradation), Rituximab, Monoclonal antibodies, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Rituximab, Monoclonal antibodies, Non-Hodgkin lymphoma (all types), Small-molecule kinase inhibitors and the tag pipeline.
Shares InnoCare Pharma and the tag pipeline.
Shares InnoCare Pharma and the tag pipeline.
Shares InnoCare Pharma and the tag pipeline.
Shares Lenalidomide, PROTACs & molecular glues (targeted protein degradation), Monoclonal antibodies and the tag pipeline.
Shares InnoCare Pharma and the tag pipeline.